StockData

Alumis vs Coya Therapeutics

ALMS and COYA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALMS and COYA compare

Alumis is the larger company, worth 9.9 times as much as Coya Therapeutics ($725M against $73.4M).

Coya Therapeutics keeps more of each dollar of sales as profit, with a net margin of −643% compared with −5845% at Alumis.

Coya Therapeutics scores higher on the StockData Score (7 against 6 for Alumis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALMSCOYA
Size and price
Market cap$725M$73.4M
Share price$5.60$3.13
Change, 1 year6.9%−48.6%
Beta (5Y)−1.121.19
Employees2248
StockData Score
Total score67 (better)
Valuation score1 (better)0
Growth score01 (better)
Performance score00
Health score56 (better)
Dividend score00
Valuation
P/S100×15.7× (better)
P/B1.9× (better)2.2×
FCF yield−44.3%–
Fair value–$2.54
Margin of safety–−23.4%
Growth
Revenue growth (TTM)–17.6%
Profitability
Operating margin−6117%−675% (better)
Net margin−5845%−643% (better)
FCF margin−4433%–
Return on equity−111%−99.2% (better)
Financial health
Debt / equity0.000.00
Current ratio5.577.24 (better)
Altman Z-score−1.673.07 (better)
Piotroski F-score23 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions91.3%33.1%
Held by insiders30.5%5.1%
Insider net buying, 12 months$44.7M–
Short interest, % of float12.3%6.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.